What is PVLA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PVLA?

P/E (TTM) is n/a and 52-week range is $65.93 to $161.38 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PVLA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PVLA?

The company profile lists revenue (TTM) near $11M, net income (TTM) near $-435M, EPS (TTM) near $-4.82 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Palvella Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Wayne, Pennsylvania, US, 14.3M shares outstanding, ISIN US6979471090 when available from company profile and filing metadata.

Palvella Therapeutics Inc (PVLA) Stock Analysis & Quote

Palvella Therapeutics Inc

$PVLA

Health Care · Biotechnology

IR Run Scenarios

$138.77

+5.66%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The company is headquartered in Wayne, Pennsylvania and currently employs 29 full-time employees. The company went IPO on 2014-12-18. The firm is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The firm's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Employees

Website

palvellatx.com/

IPO

2014-12-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)